Design Therapeutics, Inc. (DSGN), a clinical-stage biotechnology company developing gene-targeted therapies for degenerative genetic diseases, is set to present the latest developments on its eye drop candidate DT-168 for Fuchs endothelial corneal dystrophy on Friday, May 2, 2025.
DT-168 is a GeneTAC small-molecule therapy formulated as an eye drop for the treatment of Fuchs endothelial corneal dystrophy or FECD, a progressive eye disease with no approved disease-modifying therapies.
For comments and feedback contact: editorial@rttnews.com
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.